Small Cell Lung Cancer
Conditions
Keywords
irinotecan, Small Cell Lung Cancer
Brief summary
The purpose of this study is to identify the appropriate dose of irinotecan by dose escalation(dose climbing) test. The study would provide rationale for regimen decision in a future phase III clinical trial, in which irinotecan combined with cisplatin(IP) will be selected as therapeutic drugs.
Detailed description
To determine the Maximum Tolerated Dose (MTD) and Limiting Toxicity (DLTs) of irinotecan in patients with extensive stage small cell lung cancer treated with irinotecan plus cisplatin
Interventions
DRUGirinotecan
60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
Sponsors
Guangdong Association of Clinical Trials
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age 18 to 65 years, male and female 2. Histologically or cytologically confirmed extensive stage .small cell lung cancer(SCLC )（except metastases only as pleural effusion） 3. No prior chemotherapy 4. Metastatic lesion had been treated more than 14 days by palliative radiation therapy or surgery 5. With measurable tumor lesions (Non-irradiated parts),(RECIST 1.1: Without radiotherapy ,the longest diameter is more than 10mm by CT or MRI ,except that lymph nodes need short diameter need more then 15mm, and the lesions can be accurately evaluated repeatedly measurable) 6. Eastern Cooperative Oncology Group(ECOG) Performance Status 0-1 7. Expected survival ≥ 3months 8. Marrow,kidney, liver,heart and lung are well -functioning,and absolute count of * absolute neutrophil coun(ANC) ≥ 2.0 × 109 / L * blood platelet(PLT) ≥ 100 × 109 / L * Hb≥ 90g / L * conjugative bilirubin(CB)≤ upper limit of normal(ULN) × 1.5 * Aspartate transaminase(AST )(glutamic oxalacetic transaminase,GOT): ≤ upper limit of normal(ULN )× 2.5 * Alanine aminotransferase(ALT)(Glutamate Pyruvate Transaminase,GPT): ≤ ULN × 2.5 * Serum creatinine: ≤ ULN or calculated creatinine clearance≥ 60 ml / min * (PT INR) ≤ ULN × 1.5 * ECG: no abnormalities in need of treatment 9. No pregnancy or no pregnancy demand at the end of the study within six months 10. Must provide written informed consent.
Exclusion criteria
1. Patient have platinum compounds allergy history 2. Patient with active ulcer disease or chronic enteritis patients 3. Primary lesion(s) has (have) been treated by Surgery or radiation 4. Patient had received Immune drugs treatment for anti-lung cancer indications or anti-cancer Chinese traditional medicine treatment within two weeks 5. Patients with interstitial pneumonia or pulmonary fibrosis 6. Brain metastasis requiring treatment 7. Patient with bronchus or bronchial stenosis or blockage and superior vena cava syndrome caused by serious invasion 8. Patients with severe infections, severe abnormal secretion of (Anti Diuretic Hormone,ADH) syndrome, poorly controlled diabetes, severe complications requiring treatment vena cava syndrome 9. Severe cardiovascular disease: hypertension that medical treatment can not be controlled , unstable angina, myocardial infarction within the last June a history of congestive heart failure\> 3 (NYHA) and severe arrhythmia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Limiting Toxicity (DLT )in the irinotecan | up to 18 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Maximum Tolerated Dose(MTD)in the irinotecan | up to 18weeks |
Countries
China
Contacts
Primary Contactying cheng, doctor
Backup Contactqian liu, bachelor
Outcome results
None listed